|  |
| --- |
| **Supplementary** **Table 4.** Summary of TEAEs of possible decreased sympathetic functionthrough week 80 (treatment + follow-up periods) |
| **N (%) of patients** | **Tanezumab****5 mg** **(n = 92)** | **Tanezumab****10 mg** **(n = 93)** | **Celecoxib****200 mg****(n = 92)** |
| Any TEAE | 5 (5.4) | 5 (5.4) | 9 (9.8) |
| Specific TEAE\* Bradycardia Diarrhea Nausea Abdominal discomfort Orthostatic hypotension Presyncope Vomiting Dizziness postural Syncope | 2 (2.2)2 (2.2)2 (2.2)01 (1.1)0000 | 01 (1.1)1 (1.1)02 (2.2)0001 (1.1) | 1 (1.1)3 (3.3)1 (1.1)2 (2.2)1 (1.1)1 (1.1)1 (1.1)1 (1.1)0 |
| Terms included in this analysis were: abdominal discomfort; anal incontinence; anhidrosis; blood pressure orthostatic decreased; bradycardia; diarrhea; dizziness postural; early satiety; ejaculation delayed; ejaculation disorder; ejaculation failure; heart rate decreased; hypertonic bladder; hypohidrosis; micturition urgency; nausea; nocturia; orthostatic hypotension; pollakiuria; presyncope; respiratory distress; respiratory failure; sinus bradycardia; syncope; urinary hesitation; urinary incontinence; vomiting. \*Patients could have more than one specific TEAE of possible decreased sympathetic function. TEAE = treatment-emergent adverse event.TEAE = treatment-emergent adverse event. |